This study investigates the combination of two targeted agents, Ribociclib (a CDK4/6 inhibitor) and Alpelisib (a PI3K inhibitor), as a novel treatment strategy aimed at overcoming drug resistance in CRC. This evidence concerns the gene CDK4 and colorectal carcinoma.